Supernus Pharmaceuticals | SUPN

Stock Price
46.00
Daily Change
0.57 1.25%
Monthly
8.39%
Yearly
35.93%
Q3 Forecast
45.62

Peers Price Chg Day Year Date
Eisai 5,137.00 125.00 2.49% -11.57% Sep/05
Abbott 132.94 0.13 0.10% 16.68% Sep/05
Aurora Cannabis 6.78 0.09 1.35% -7.50% Sep/05
ANI Pharmaceuticals 95.35 -0.65 -0.68% 57.58% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Corcept Therapeutics 69.36 -0.01 -0.01% 101.75% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Novo Nordisk A/S 350.00 -10.50 -2.91% -60.30% Sep/05
Pacira 26.45 -0.28 -1.05% 90.97% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Perrigo 23.49 -0.25 -1.05% -19.14% Sep/02
Supernus Pharmaceuticals 46.00 0.57 1.25% 35.93% Sep/05
United Therapeutics 400.52 20.05 5.27% 15.88% Sep/05
Canopy Growth 2.02 0.11 5.76% -66.72% Sep/05
Xeris Pharmaceuticals 7.85 -0.04 -0.51% 212.75% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Supernus Pharmaceuticals traded at $46.00 this Friday September 5th, increasing $0.57 or 1.25 percent since the previous trading session. Looking back, over the last four weeks, Supernus Pharmaceuticals gained 8.39 percent. Over the last 12 months, its price rose by 35.93 percent. Looking ahead, we forecast Supernus Pharmaceuticals to be priced at 45.62 by the end of this quarter and at 44.49 in one year, according to Trading Economics global macro models projections and analysts expectations.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.